Search Results

Antipsychotics: NMS (fluphenazine) and elevated serum CK levels (risperidone, olanzapine, quetiapine and ziprasidone): case report

Source: Reactions, Volume 1, Number 1266, 2009-08-22 , pp. 8-8(1)

Publisher: Adis International

Amisulpride/venlafaxine: Catatonia, NMS and temporal lobe epilepsy after venlafaxine withdrawal: case report

Source: Reactions, Volume 1, Number 1267, 2009-08-29 , pp. 6-7(2)

Publisher: Adis International

Neuroleptic Malignant Syndrome Associated with Atypical Antipsychotic Drugs

Authors: Trollor, Julian N.; Chen, Xiaohua; Sachdev, Perminder S.

Source: CNS Drugs, Volume 23, Number 6, 30 May 2009 , pp. 477-492(16)

Publisher: Adis International

A Case of Neuroleptic Malignant Syndrome Induced by Risperidone in a Schizophrenic Woman

Authors: Gallelli, Luca; Spagnuolo, Vincenzo; Palleria, Caterina; De Sarro, Giovambattista; Ferraro, Maria

Source: Current Drug Safety, Volume 4, Number 2, May 2009 , pp. 119-120(2)

Publisher: Bentham Science Publishers

Atypical Neuroleptic Malignant Syndrome or Serotonin Toxicity Associated with Atypical Antipsychotics?

Author: Odagaki, Yuji

Source: Current Drug Safety, Volume 4, Number 1, January 2009 , pp. 84-93(10)

Publisher: Bentham Science Publishers

Olanzapine-induced neuroleptic malignant syndrome in a patient with paranoid schizophrenia

Authors: Srivastava, Ashish; Borkar, Hirabai A.; Chandak, Sumitkumar

Source: Psychiatry and Clinical Neurosciences, Volume 63, Number 1, February 2009 , pp. 119-121(3)

Publisher: Blackwell Publishing

Neuroleptic malignant syndrome (NMS) is associated with antipsychotic use in patients with bipolar disorder

Source: Reactions, Volume 1, Number 1208, 2008-06-28 , pp. 4-4(1)

Publisher: Adis International

Catatonic Variants, Hyperthermic Extrapyramidal Reactions, and Subtypes of Neuroleptic Malignant Syndrome

Author: Lee, Joseph

Source: Annals of Clinical Psychiatry (after Jan 1, 2004), Volume 19, Number 1, January 2007 , pp. 9-16(8)

Publisher: Informa Healthcare

Catatonic Variants, Hyperthermic Extrapyramidal Reactions, and Subtypes of Neuroleptic Malignant Syndrome

Author: Lee, Joseph

Source: Annals of Clinical Psychiatry (after Jan 1, 2004), Volume 19, Number 1, January 2007 , pp. 9-16(8)

Publisher: Taylor and Francis Ltd

NMS occurs with all atypical antipsychotics − ADRAC

Source: Reactions, Volume 1, Numbers 1146-1147, 2007-04-07 , pp. 2-2(1)

Publisher: Adis International

Postoperative neuroleptic malignant syndrome that occurred repeatedly in a patient with cerebral palsy

Authors: TSUCHIYA, NAOHISA; MORIMURA, ERI; HANAFUSA, TETSUJI; SHINOMURA, TETSUTARO

Source: Paediatric Anaesthesia, Volume 17, Number 3, March 2007 , pp. 281-284(4)

Publisher: Blackwell Publishing

Brain injury following neuroleptic malignant syndrome: Case report and review of the literature

Authors: Labuda, Anna; Cullen, Nora

Source: Brain Injury, Volume 20, Number 7, July 2006 , pp. 775-778(4)

Publisher: Informa Healthcare

Pharmacogenetic Aspects of Neuroleptic Malignant Syndrome

Authors: Kawanishi, Chiaki; Kishida, Ikuko; Furuno, Taku; Kato, Daiji; Bertilsson, Leif

Source: Current Pharmacogenomics, Volume 4, Number 2, June 2006 , pp. 113-119(7)

Publisher: Bentham Science Publishers

Atypical neuroleptic malignant syndrome caused by olanzapine

Authors: Nielsen, J.; Bruhn, A. M.

Source: Acta Psychiatrica Scandinavica, Volume 112, Number 3, September 2005 , pp. 238-240(3)

Publisher: Blackwell Publishing

CYP2D6 gene deletion allele in patients with neuroleptic malignant syndrome: Preliminary report

Authors: KATO, DAIJI; KAWANISHI, CHIAKI; KISHIDA, IKUKO; FURUNO, TAKU; MATSUMURA, TAKEHIKO; HASEGAWA, HANA; SUZUKI, KYOKO; HIRAYASU, YOSHIO

Source: Psychiatry and Clinical Neurosciences, Volume 59, Number 4, August 2005 , pp. 504-507(4)

Publisher: Blackwell Publishing

Drug-induced movement disorders in children and adolescents

Author: Robert L Rodnitzky

Source: Expert Opinion on Drug Safety, Volume 4, Number 1, 1 January 2005 , pp. 91-102(12)

Publisher: Informa Healthcare

Drug-induced hyperthermia in Huntington's disease

Authors: Gaasbeek, D.; Naarding, P.; Stor, T.; Kremer, H.

Source: Journal of Neurology, Volume 251, Number 4, April 2004 , pp. 454-457(4)

Publisher: Springer

Neuroleptic malignant syndrome: risk factors, pathophysiology, and treatment

Authors: Jambur Ananth; Kamala Aduri; Sharath Parameswaran; Sarath Gunatilake

Source: Acta Neuropsychiatrica, Volume 16, Number 4, August 2004 , pp. 219-228(10)

Publisher: Blackwell Publishing

Risk factors in neuroleptic malignant syndrome. A case–control study

Authors: Viejo L.F.; Morales V.; Puñal P.; Pérez J.L.; Sancho R.A.

Source: Acta Psychiatrica Scandinavica, Volume 107, Number 1, January 2003 , pp. 45-49(5)

Publisher: Blackwell Publishing

Neuroleptic malignant syndrome following cardiac surgery: successful treatment with dantrolene

Authors: Mieno S.; Asada K.; Horimoto H.; Sasaki S.

Source: European Journal of Cardio-Thoracic Surgery, Volume 24, Number 3, September 2003 , pp. 458-460(3)

Publisher: Elsevier